Member Info for Doc.Daneeka

So Acting CMO can't do as good a job as CMO then Gunto ? Perhaps you'll explain the magic that happens when he gets the big job when we thought he had already been doing it. As you understand it so well.

If Acting CMO was a part time post then of course he can contribute much more if he becomes full time. Is that what Fruits means ? Was he part time until this announcement ?

I'm not triggered Fruits - you posted yet another load of bollo.xios. Even by your standards it was poor, pathetic even. And I've pointed it out.

Well ok Gunto - what's your asseessment of the importance of Mankowski moving from "acting " CMO to CMO.

Is it good enough to merit Fruits wild excitment ( which I can't remember him sharing at the time of the announcement)

Is he the "canary in the goldmine " or is it just a little bit of nothing.

Are we in a better position with Mankowski confirmed in the role - after the 4 years doing it for fun

Done with you - maybe i should have said Gunto.

Great post by the way Fruits. The canary in the goldmine is.........drum roll ............... Marcin Mankowski. !!!!

The same Mankowski who has been doing the exact same job in an acting capacity since 2018. Not only is this not "part of an orchestrated plan" but your canary was in the building when they passed the Sprinter protocols. In the building when they failed to produce enough drug to start Activ 2 on time, in the building when they sat on the COPD data for 4 years and has been in the building for the 3 changed start dates for the P2s.

He's probably brilliant on a yacht in a stiff sou'westerly or paired with PM in the Sunday foursomes but his track record

as a CMO leaves a lot to be desired.

Andrewp I thought lots of people heard this and reported on it ?

Sure Doc83 and Wigster et al will have notes.

You've become a gibbering idiot Gunto. Cackling and spluttering nonsense from the sidelines without an ounce of wit or insight. Anyway I'm done with all of it. Let's have a start date - let's see the protocols and authorisations and how many sites. That's all that matters now.

Remember that Td is on the meter - this becomes more apparent with every single post he uses to attack LTHs who were supporting this share and company long before he got the call to get busy the morning after Sprinter failed in Feb 22. The rest of us are just interested in whether Synairgen can get this once very promising drug over the line - despite the many failures since SG016.

There will be patients available all year round of course - and with trials sizes not expected to exceed 50 patients, the mini P2s should fill easily. COPD deaths peak in early spring but across the board the patients won't be as sick if the trials are filled in the summer or autumn. We know that twice as many respiratory patients are hospitalized in the winter and many have serious outcomes (often as a result of multiple simultaneous infections ( Twice as many die. You may say this is irrelevant as we don't need many - but of course we need the most at-risk patients to fill these trials.

We are expecting that the inclusion criteria will focus in so sharply on those who are predestined for poor outcomes that it's inevitable that the P2s will fill much more slowly in spring, summer and autumn. It'll be harder to identify the patients needed for the right outcome

Relating this to yesterday's slogathon between Mani and Tp - after his Tommy's relentlessly regurgitated "enough patients in 2 days to fill our trial " is the fact that Td's numbers are for every hospital in the country. And there are 1148 of them. SG016 was run in 6 hospitals. As far as we know UNIVERSAL in just 2 ( Soton and Dundee) . So until we know how many sites there will be for the P2s it's impossible and ridiculoius to make statistical predictions of this nature. To post it half a dozen times is even more ridiculous

And as TP says until we have the protocols and start date it's largely irrelevant to even be talking about how easy it'll be to fill the trials.

We're only halfway through January so plenty of time to go before we need to worry that we have missed the winter season - but it really IS a season and the patients recruited in it will be better patients for us. When the trials were first announced they intended to catch the winter of 23/24 - and despite the stoic rearguard action being fought by the likes of Fruits and Td, the company will be disappointed to miss it.

Oh go away gunto - Fruits directs a couple of posts straight at me - I respond.

Yaboo Fruitsnvoc. I take Covid as seriously as any poster on this board. I just don't pay much attention to your constant phony canary in the coalmine routine. When you squawk you're not reminding us to take care - or flagging up a genuinely new concern in the global or scene - you're doing it to support your investment that's been dribbling further away with every new variant.

The reality is that Synairgen's fate has nothing to do with the evolution of C-19. RM told us this several times this year. It once was entwined with it - for the brief moment after SG016 when the company could have found a partner or platform trial and got itself authorised and saved some lives - but that moment had gone by the start of 2022, and until the P2s are complete and give us a P3 it won't come back.

Post about COPD or RSV or Viral Pneumonia if you really have to keep squawking away - but assume we're all up to date on C19.

They did Aether :)

You've gone cmpletely mnad. You posted your snarky little "lol" and i replied to it using your username.

Who is the other poster you imagine i was talking to ? Bit worrying gunto really. Screw loose territory

Anyway - nice chatting with you gunto - or whoever you are. Just wanted to correct Fruitsnvocs most recent armageddon post. Expecting another uptick in hospitalisations when the return to school mini wave comes through, but relieved - as ever - that JN.1 is just another friendly strain of Omicron. And we're not interested in Covid anyway - so all is well.

Enjoy your day

I called you gunto ?

" the mask slipped" is hilarious - you and your pathetic pals seeing reds under eery bed and ranks of spies and 5th columnists.

Not a phrase you're familiar with gunto ? Language is funny like that - you can snip a little piece and present it any way you want - or you can look at the whole thing and see the truth.

There is still concern - particularly with waning immunity - but a 7% rise in admissions in the week after Christmas and New Year is piffling

For balance

Here's a few more quotes from that same Indy piece - to set alongside Fruitsnvoc's habitual one-eyed hysteria. Not a different souce - the exact same source.

"the rise in hospital cases remains “very modest”

Professor Pollard " pointed to “good news” in the data showing a drop in the percentage of positive cases sequenced by the UKHSA – which he said suggests that hospital cases will also soon start to fall. "

"Professor Paul Hunter also said England appears to be “past the peak of the latest wave” and that the number of patients occupying NHS beds primarily because of Covid “also seems to have plateaued”.

God that's a yawn. 6 hours stewing on my little post and then coming back with this nasty piece of nothing. And you're angry because I've written something that you actually agree with - even to the extent of claiming it as your own work. Well make your mind up fella. I either ripped you off - or I'm writing cra.pola. Can't be both. (although obviously it could)

Let me explain both comments - the context is in the longer posts anyway but that's who you are isn't it - a tiresome cut and paste merchant who loves to skew perceptions.

"“The first batch of released data from UNIVERSAL told us very little - but it was just the surface skim. The deep analysis will reveal much more. "

This is still true and not contradicted by anything i wrote today - we're waiting for something substantive aren't we. Nothing posted today changes that. Both of the markers Thinshins posted are consistent and predictable for patients with a severe respiratory infection. Low white blood cell count ( Lymphopenia ) and an elevated marker of bacterial infection ( CRP>55) Hardly ground breaking medical research - but hopefully useful for the future.

The second point relates specifically to my contention that the ageing team of medicos at Synairgen could not have devized a clever new test. Again this is not inconsistent - it seemed unlikely a few day ago when i wrote it and it's self evidently true today. I mean I'd love to see it but I don't think the old buffers have got it in them.

The scientists haven't discovered anything new. They're just honing the inclusion criterion for the next trials using the old traditional methods - and hopefully with a splash of Casanovalabs added to the mix.

You're upset - I can see it. But that's ok. Working the hours you do. Get some sleep. Call mother for some new material in the morning - and come back re-charged with something better.

Thanks Mani by the way.

Thanks Thinshins. I'm with you - I don't know if " Lymphopenia and CRP>55 mg/L " are markers that can be identifed in advance - or how strong the association with severe disease was ( presumably they'd have given a % if it was significant)

Pusillanimity is another great P word Tommy. My posts are original. Yours are fed to you by whoever sent you here the day after Sprinter crashed and keeps you chained to your desk trying to control the debate. If you agree with something I've written - that's of course very welcome. Well done you. .

It's for discussion anyway - as UNIVERSAL is often in our thoughts, and it's useful to remind the board that it is not going to unlock all the doors but create a bridge that allows regulators to allow these trials to progress.

For a long while I've been thinking that the company was preparing a new diagniostic test or tests - something they've developed and used in UNIVERSAL and were honing in readiness for the P2s. A super-test if you like or even a piece of hardware. But I now think this is wide of the mark.

What we'll get - instead - is a much more targeted set of inclusion criteria - based on Sprinter's deep dive, and perhaps augmented by anything new that UNIVERSAL reveals. Key features being Age / Oxygen saturation & Co-morbidities. We're all hoping that Casanovalabs is involved, ( their participation has not been confirmed by anything other than off the record barroom chat - but the stars do seem to have aligned with the most recent research paper from them ) Casanovalabs could provide their IfN auto-ab test, which might even have been used on UNIVERSAL and should certainly help to find a good cohort of the P2 patients, but it's not the most important aspect of what is to come.

And this is positive. I had concerns whether the company could create a revolutionary test without huge external assistance - but if they're "just" refining the inclusion criteria - and deciding how to balance the different determinants in setting the new protocols - then that's a much faster and easier road.

We should remember that in the Interim report in June 23, Synairgen highlighted viral pneumonia and mentioned ventilated patients, viral shedders and immunocompromised patients as the areas they were interested in.

Really really sick patients - and a world away from the loosely identified mass-targeting of Sprinter( positive for C19 and maybe lo-flow oxygen - but not always). Casanovalabs assays should help id the 2 and 3rd of these - but SNG001 has never been trialed with ventilators and it remains to be seen if any of the 300 UNIVERSAL patients will have reached this stage and have anything useful to offer. Ventilated patients on SNG001 would be something to see..

UNIVERSAL is critical in joining the dots between a multitude of respiratory viruses - and demonstrating that Synairgen's Covid and COPD data and SNG's method of action can read across to all viruses - but the Covid data from Sprinter, and the viral clearance data from the COPD study are overwhelmingly going to be the most important factors in designing the new trials.

" Conducting non-interventional preparatory work to expand hospitalised patient populations for potential treatment with SNG001, which are likely to include: ventilated patients with confirmed viral pneumonia; and patients who are unable to clear virus and become persistent viral “shedders”, a majority of whom are immunocompromised. Subject to this preparatory work and regulatory approval timelines, trials are anticipated to start in H1 2024.

Insights from non-interventional studies and the substantial body of evidence gathered to date from previous clinical trials will inform a robust clinical programme for the development of SNG

That patent is really interesting Brand. Designed principally as a tool for patients with Covid 19 or to check vulnerabilities for those about to receive LAV vaccines

"In accordance with the invention and as described herein, at least or about 10% of patients with life threatening COVID-19 pneumonia have neutralizing auto-antibodies (auto-Abs) against type I IFNs....The invention provides assays and methods for identification and characterization of auto-antibodies against Type I IFNs that are associated with severe COVID-19 disease "

Which is exactly what is needed to find the patient population for SNG - but of course across the range of conditions. rather than just C-19.

We've expected Casanovalabs to be involved since the AGM - so nothing posted about this in the last day or 2 is particularly revelatory. The question is whether Auto/ab assays are enough on their own. I assumed they were working on something else with the existing and UNIVERSAL data.

If there isn't anything else - but they have a test that identifies the 10% with life threatening Covid pneumonia - and the test works to identify life threatening pneumonia in the other areas of interest, ie all RVAs - - then that's enough. It's a small subset of a small subset but provided SNG001 makes a huge difference for these patients it's enough.